BIO-Europe Spring® 2016: Italy's A. Menarini IFR aims to expand into the US and Japan

May 18, 2016
A. Menarini IFR corporate licensing director Giammario Piras speaks to Informa senior editor and writer Sten Stovall during the BIO-Europe Spring® partnering conference in Stockholm, Sweden, about the Italian pharma group's geographic business plans and hopes for penetrating the US market. In-licensing drugs for therapeutic areas of oncology and cardiovascular will be used, while US entry via M&A is also an option, Piras says, adding that entering Japan might prove harder to do but is nonetheless a priority.
Previous Video
BIO-Europe Spring® 2016: Strategic unit at MD Anderson forges creative alliances
BIO-Europe Spring® 2016: Strategic unit at MD Anderson forges creative alliances

Shara Avis, business development specialist at MD Anderson Cancer Center—a world-renown research center—spe...

Next Video
BIO-Europe Spring® 2016: BeyondSpring Pharmaceuticals outlines Plinabulin plans
BIO-Europe Spring® 2016: BeyondSpring Pharmaceuticals outlines Plinabulin plans